+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range



Triple antithrombotic therapy is the independent predictor for the occurrence of major bleeding complications: analysis of percent time in therapeutic range



Circulation. Cardiovascular Interventions 6(4): 444-451



Triple antithrombotic therapy increases the risk of bleeding events in patients undergoing percutaneous coronary intervention. However, it remains unclear whether good control of percent time in therapeutic range is associated with reduced occurrence of bleeding complications in patients undergoing triple antithrombotic therapy. This study included 2648 patients (70 ± 11 years; 2037 men) who underwent percutaneous coronary intervention with stent in the Ibaraki Cardiovascular Assessment Study registry and received dual antiplatelet therapy with or without warfarin. Clinical end points were defined as the occurrence of major bleeding complications (MBC), major adverse cardiac and cerebrovascular event, and all-cause death. Among these 2648 patients, 182 (7%) patients received warfarin. After a median follow-up period of 25 months (interquartile range, 15-35 months), MBC had occurred in 48 (2%) patients, major adverse cardiac and cerebrovascular event in 484 (18%) patients, and all-cause death in 206 (8%) patients. Multivariable Cox regression analysis revealed that triple antithrombotic therapy was the independent predictor for the occurrence of MBC (hazard ratio, 7.25; 95% confidence interval, 3.05-17.21; P<0.001). The time in therapeutic range value did not differ between the patients with and without MBC occurrence (83% [interquartile range, 50%-90%] versus 75% [interquartile range, 58%-87%]; P=0.7). However, the mean international normalized ratio of prothrombin time at the time of MBC occurrence was 3.3 ± 2.1. Triple antithrombotic therapy did not have a predictive value for the occurrence of all-cause death (P=0.1) and stroke (P=0.2). Triple antithrombotic therapy predisposes patients to an increased risk of MBC regardless of the time in therapeutic range.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056693672

Download citation: RISBibTeXText

PMID: 23941857

DOI: 10.1161/circinterventions.113.000179


Related references

Adequate time in therapeutic INR range using triple antithrombotic therapy is not associated with long-term cardiovascular events and major bleeding complications after drug-eluting stent implantation. Journal of Cardiology 68(6): 517-522, 2016

Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting. Chest 134(3): 559-567, 2008

Ticagrelor in Triple Antithrombotic Therapy: Predictors of Ischemic and Bleeding Complications. Clinical Cardiology 39(1): 19-23, 2016

Bleeding complications of triple antithrombotic therapy after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions 89(2): E64-E74, 2017

Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. European Heart Journal 32(18): 2282-2289, 2011

Bleeding complications after implantation of active cardiovascular implantable devices in an era of triple therapy and novel antithrombotic drugs. European Heart Journal 34(Suppl 1): P3653-P3653, 2013

Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. Journal of Thrombosis and Thrombolysis 35(2): 178-184, 2013

Antithrombotic therapy - predictor of early and long-term bleeding complications after transcatheter aortic valve implantation. Archives of Medical Science 9(6): 1062-1070, 2013

A new scoring system (DAIGA) for predicting bleeding complications in atrial fibrillation patients after drug-eluting stent implantation with triple antithrombotic therapy. International Journal of Cardiology 223: 985-991, 2016

Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation 139(6): 775-786, 2019

The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. Balkan Medical Journal 34(4): 349-355, 2017

Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. Journal of Cardiology 65(3): 197-202, 2015

Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. Canadian Journal of Cardiology 29(2): 204-212, 2013

Occurrence of cirrhosis-related complications is a time-dependent prognostic predictor independent of baseline model for end-stage liver disease score. Liver International 26(1): 55-61, 2006

After PCI in AF, dual antithrombotic therapy with dabigatran reduced bleeding compared with triple therapy. Annals of Internal Medicine 167(12): Jc70, 2017